Scribe Therapeutics files S-1 for Nasdaq IPO under ticker SCTX
The clinical-stage CRISPR company disclosed plans to list on Nasdaq as it advances its lead LDL-C program, STX-1150, through a first-in-human trial in Australia.
Scribe Therapeutics Inc. filed an S-1 registration statement with the SEC on July 2, 2026, for an initial public offering of common stock. The company has applied to list its common stock on the Nasdaq Global Market under the symbol "SCTX."1
The company describes itself as a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention1, with a focus on cardiovascular and metabolic diseases with initial programs to address the key drivers of atherosclerotic cardiovascular disease, or ASCVD1.
Scribe's pipeline rests on two distinct proprietary technologies built from a shared CRISPR-CasX enzyme platform. As the filing states, the company has engineered two proprietary technologies based on a novel CRISPR-CasX enzyme: the Epigenetic Long-Term X-Repressor, or ELXR, designed for precise, durable epigenetic silencing without altering the underlying DNA sequence; and the X-Editor, or XE, designed for specific and efficient gene editing1. ELXR and XE serve different functions: ELXR turns genes off through epigenetic marks without changing DNA, while XE performs actual gene editing.
The lead candidate, STX-1150, uses the ELXR platform. STX-1150 is an epigenetic silencing therapy that is based on ELXR technology and is designed to durably lower LDL-C by repressing the expression of PCSK91. Scribe has secured regulatory clearance from the Australian Therapeutic Goods Administration for and initiated a first-in-human clinical trial of STX-1150 in Australia in up to 64 adults with elevated LDL-C and increased risk of ASCVD1, with initial data, including safety, tolerability, and LDL-C-lowering activity, anticipated in the first half of 20271.
Two additional candidates, STX-1200 and STX-1400, use the XE gene-editing platform. These target LPA and APOC3 genes to address elevated Lp(a) and severely high triglycerides, respectively1. With CIRM funding support, the company anticipates initiating a Phase 1 trial for one of these programs as early as 2027 and the other in 2028.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.